Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
National Institute of Allergy and Infectious Diseases (NIAID)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Chronic HIV-1 infected individuals presently on HAART with no change in drug combination for at least 3 months at time of enrollment
2. Plasma viral load \<200 copies / ml for at least 6 months prior to enrollment in the study
3. CD4 T cell count more than 350/ul
4. Willingness to use a method of contraception during the study period
5. Willingness to have blood drawn
6. If female, willingness to undergo pregnancy testing on a monthly basis and are not breastfeeding
7. Ability to understand and willingness to sign the informed consent
8. hs-CRP levels above the upper limit of normal (\>3mg/L)
You may not be if
1. Concomitant use of fibric acid derivatives or other lipid lowering agents including patients on statins and Ezetimibe
2. Use of any anti-inflammatory drugs (OTC or prescription) on a daily basis
3. Pregnancy or breast feeding
4. Active drug use or alcohol abuse/dependence, which in the opinion of the investigators will interfere with the patient's ability to participate in the study
5. Allergy or hypersensitivity to statins or any of its components
6. History of myositis or rhabdomyolysis with use of any statins
7. Patients who are on concurrent immunomodulatory agents, including systemic corticosteroids will be ineligible for 3 months after completion of therapy with the immunomodulating agents
8. History of inflammatory muscle disease such as poly or dermatomyositis
9. Serious intercurrent illness requiring systemic treatment and/or hospitalization within 30 days of entry
10. Evidence of active opportunistic infections requiring treatment or neoplasms that require chemotherapy during the study period
11. Creatine phosphokinase elevations (CPK) greater than 3 times the upper limit of normal
12. Known active liver disease or AST/ALT greater than 2x the upper limit of normal
13. Renal insufficiency, indicated by serum creatinine 2 mg/dl
14. Absolute neutrophil count (ANC) 1000/mm3, hemoglobin \< 10.0 g/dL for males and \<9 g/dL for females, platelet count 100,000/mm
Clareo Health | Modulation of Monocyte Activation by Atorvastatin in HIV Infection
